Milestone in clinical study for chronic migraine treatment
Salvia BioElectronics has announced its first migraine therapy implant in The Netherlands at Erasmus MC in Rotterdam. This marks a significant step in an ongoing clinical study that spans Belgium, Australia, and now The Netherlands, with Antonius Hospital Utrecht/Nieuwegein also joining the trial.
Key Details:
- The therapy consists of two ultra-thin implants, one placed on the forehead and the other on the back of the head.
- The wearable external device allows patients to activate neuromodulation therapy with a simple button press.
- This therapy aims to reduce migraine frequency and intensity by delivering gentle electrical pulses to nerves associated with chronic migraines.
Salvia’s ultimate goal is to offer a non-invasive solution for chronic migraine sufferers, providing a new treatment option under the care of neurologists.
Follow MEDWIRE.AI for further updates on innovations in migraine treatment and neuromodulation therapies.
